Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE

Conclusion: We observed a meaningful disease control rate of 72% during treatment of WD HG NETs with177Lu-DOTATATE. In this heavily pre-treated population, more than half of patients received all four treatment cycles with toxicities largely bone marrow-related. As would be expected in WD NETs, the vast majority had alterations in chromatin remodeling genes and no RB1 alterations.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research